Entity

Time filter

Source Type


Zhang Z.,Beijing University First Hospital | He F.,First Renmin Hospital | Shi Y.,Renmin Hospital
Rheumatology International | Year: 2013

For the purpose of investigating Behcet's disease in China, all the patients diagnosed as Behcet's disease in our hospital during the past 2 years were recruited into the study. The clinical and laboratory data of the patients were recorded and further analyzed; 334 patients were included with 195 males and 139 females. The mean age at onset was 35.8 ± 11.1 years. The most frequent initial manifestations were oral aphthae and genital ulceration. The common manifestations observed throughout the disease course were oral aphthae, genital ulceration and various cutaneous lesions. Besides these, many organs/systems including joint, eye, vessel, gastrointestine, nervous system, cardiovascular system, and pulmonary system were also involved in 28.4, 26.1, 17.4, 16.8, 9.6, 8.1, and 4.8 % of our patients, respectively. Involvement of ocular and vascular was more common in males than in females. Behcet' disease most frequently affects the Chinese patients aged 30-39 and displays a wide clinical spectrum with varieties of severe internal organ involvement. The disease is more common and severe in males than in females in Chinese populations. © 2012 Springer-Verlag. Source


Liu B.,Jilin University | Huo Y.,Beijing University First Hospital | Shi J.F.,Jilin University | Li Y.L.,Changchun University of Science and Technology
Laser Physics Letters | Year: 2013

We report for the first time coherent ultraviolet radiation at 299 nm by intracavity sum-frequency generation of an 899 nm Nd:YAG laser and a 456 nm frequency doubling Nd:GdVO4 laser. The ultraviolet laser is obtained by using doubly resonant, type-I critical phase matching CsLiB6O10 (CLBO) crystal sum-frequency mixing. With a total diode pump power of 35.6 W (17.2 W pump power for the 899 nm Nd:YAG laser and 18.4 W pump power for the 456 nm Nd:GdVO4 frequency doubling laser), a TEM00 mode ultraviolet laser at 299 nm of 331 mW is obtained. The power stability is better than 3.4% and the laser beam quality M2 factors are 1.22 and 1.17 in the horizontal and vertical dimensions respectively. © 2013 Astro Ltd. Source


Jiang Y.,Beijing University First Hospital
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences | Year: 2013

To investigate the diagnostic value of clinical manifestations, pathologic findings of skin biopsies and genetic testing in the diagnosis of neonatal hereditary dystrophic epidermolysis bullosa. Here we reported one case of hereditary dystrophic epidermolysis bullosa with neonatal onset, and explored the clinical and pathological features,as well as the genetic diagnosis,of the disease process. The neonate was born with large areas of skin damage and erosion, extending to the left ankle and foot, and was admitted to the hospital 10 hours after birth. Hemophysallis and blisters were found in her mouth, and during her hospital stay the patient developed multiple bullae, skin peeling and skin erosion at the compressed and friction areas of the body. Bacterial cultures from both the skin erosion and oral secretions were negative. Pathology of the skin showed a small amount of loose connective tissue visualized by light microscopy. Visualization with electron microscope revealed no basal layer in the majority of the skin, tonofilament scattered in the dermal tissue, and basement membrane with unclear anchoring fibril and thinner lamina densa in a portion of the region studied. Consequently,the diagnosis of dystrophic epidermolysis bullosa was made. COL7A1 gene tests were subsequently performed on the patient's family. Insertion of AGGG fragment was found at the 500th locus of exon 13 in the mother's COL7A1 gene. The patient's father had a G-to-A mutation at the splicing locus after exon 98. The neonate had complex heterozygous mutation in COL7A1 gene consistent with the father and mother's mutation, which led to the development of the disease. The parents,who were carriers of the disease-causing genes,both had a normal phenotype. Skin pathology was indicated for the diagnosis of clinically suspicious hereditary dystrophic epidermolysis bullosa. The microstructure visualized in the pathologic findings aided in making the preliminary classification, and further genetic testing was able to be performed according to the pathological classification. Genetic testing of the parents could greatly aid family planning in the future. Source


Jing Z.-C.,Tongji University | Yu Z.-X.,Central South University | Shen J.-Y.,Shanghai JiaoTong University | Wu B.-X.,Haerbin Medical University | And 8 more authors.
American Journal of Respiratory and Critical Care Medicine | Year: 2011

Rationale: Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy with these agents has not been conclusively shown to reduce clinical worsening events. Objectives: To evaluate the safety and efficacy of the phosphodiesterase type 5 inhibitor vardenafil in Chinese patients with PAH. Methods: In a randomized, double-blind, placebo-controlled study, 66 patients with PAH were randomized 2:1 to vardenafil (5 mg once daily for 4wk then 5mg twice daily; n=44) or placebo (n=22) for 12 weeks. Patients completing this phase were then treated with openlabel vardenafil (5 mg twice daily) for a further 12 weeks. Measurements and Main Results: At Week 12, the mean placebocorrected 6-minute walking distance was increased with vardenafil (69 m; P<0.001), and this improvement was maintained for at least 24 weeks. Vardenafil also increased the mean placebo-corrected cardiac index (0.39 L·min-1·m-2; P = 0.005) and decreased mean pulmonary arterial pressure and pulmonary vascular resistance (-5.3 mm Hg, P = 0.047; -4.7 Wood U, P = 0.003; respectively) at Week 12. Four patients in the placebo group (20%) and one in the vardenafil group (2.3%) had clinical worsening events (hazard ratio 0.105; 95% confidence interval, 0.012-0.938; P = 0.044). Vardenafil was associated with only mild and transient adverse events. Conclusions: Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily. Source


Objective: To explore the efficacy of Jinghuaweikang capsules plus triple therapy (LACJ) in treatment of Helicobacter pylori (H. pylori) associated gastritis or duodenal ulcer, compare it with bismuth-containing quadruple therapy (LACB) and standard triple therapy (LAC) and analyze the antibiotic sensitivity of gastric mucosal H. pylori strains from the failed patients. Methods: A total of 565 patients with H. pylori infection were recruited from 11 hospitals from January 2010 to June 2011. There were 336 males and 229 females. They underwent gastroendoscopy examination due to upper gastrointestinal symptoms and had never received H. pylori eradication therapies. Duodenal ulcer patients were divided randomly into LACJ therapy group, LACB therapy group and LAC therapy group while gastritis patients LACJ therapy group and LACB therapy group. Group LAC received lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg, twice a day, for 7 d (d1 - 7). Group LACJ: LAC therapy plus Jinghuaweikang, 3 capsules, twice a day, for 7 d (d1 - 7) then Jinghuaweikang, 3 capsules, twice a day, for 14 d (d8 - 21). Group LACB: LAC plus bismuth potassium citrate 220 mg, twice a day, for 7 d (d1 - 7) and then bismuth potassium citrate 220 mg, twice a day, for 14 d (d8 - 21). All duodenal ulcer patients received lansoprazole (30 mg, once a day) for 14 days after the first 7-day of treatment (d8 - 21). At least 28 days after the end of treatment, all patients underwent C urea breath test. Gastric mucosa was collected under endoscopy from the failed patients. The detection technique of gene chip was employed to detect antibiotics resistant gene from mucosa. Results: The eradication rates of duodenal ulcer patients in groups LACJ, LACB and LAC were as follows; per-protocol (PP), 80.2% (77/96), 89.9% (89/99) and 72.2% (70/97) (P=0.007), intention-to-treat (ITT), 78.6% (77/98), 88.1% (89/101) and 70.0% (70/100) (P = 0.007). No statistical differences existed between groups LACJ and LACB or LAC (all P > 0.05). But there were statistical differences between groups LACB and LAC (both P = 0.002). The eradication rates of PP and ITT of chronic gastritis patients in groups LACJ and LACB were as follows; 75.8% (97/128), 74.6% (97/130) vs 83.8% (109/130), 80.1% (109/136) (both P > 0.05). The symptomatic improvements of abdominal pain, burning and acid reflux of duodenal ulcer patients in group LACJ were higher than those in groups LACB and LAC. There were statistical differences between groups LACJ and LAC (all P < 0.05). The symptomatic improvements of bloating and belching for chronic gastritis patients in group LACJ were higher than those of group LACB. But no significant difference existed between two groups (all P > 0.05). Sixty samples of gastric mucosa were collected from the failed patients. The detection rates of antibiotic-resistant gene to clarithromycin and amoxicillin were 60.0% (36/36) and 18.3% (11/60) respectively. Conclusions: The efficacy of LACJ for the treatment of H. pylori infection patients is similar to LACB and superior to LAC. And the symptomatic improvement of patients is better than the other two regimens. The main cause of treatment failure is antibiotic resistance of H. pylori strains. Copyright © 2012 by the Chinese Medical Association. Source

Discover hidden collaborations